Cited by

• FOXO1 inactivation induces cisplatin resistance in bladder cancer.

  Ide H, Goto T, Teramoto Y, Mizushima T, Jiang G, Nagata Y, Inoue S, Baras AS, Kashiwagi E, Miyamoto H. Ide H, et al. Cancer Sci. 2020 Sep;111(9):3397-3400. doi: 10.1111/cas.14557. Epub 2020 Jul 17. Cancer Sci. 2020. PMID: 32678492 Free PMC article.
• GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer.

  Tatenuma T, Matsukawa T, Goto T, Jiang G, Sharma A, Najafi MAE, Teramoto Y, Miyamoto H. Tatenuma T, et al. Cancer Genomics Proteomics. 2024 Nov-Dec;21(6):557-565. doi: 10.21873/cgp.20472. Cancer Genomics Proteomics. 2024. PMID: 39467629 Free PMC article.
• Amyloids in bladder cancer hijack cancer-related proteins and are positive correlated to tumor stage.

  Alem D, García-Laviña CX, Garagorry F, Centurión D, Farias J, Pazos-Espinosa H, Cuitiño-Mendiberry MN, Villadóniga C, Castro-Sowinski S, Fló M, Carrión F, Iglesias B, Madauss K, Canclini L. Alem D, et al. Sci Rep. 2025 Feb 5;15(1):4393. doi: 10.1038/s41598-025-88307-7. Sci Rep. 2025. PMID: 39910105 Free PMC article.
• Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.

  Goto T, Kashiwagi E, Jiang G, Nagata Y, Teramoto Y, Baras AS, Yamashita S, Ito A, Arai Y, Miyamoto H. Goto T, et al. Am J Cancer Res. 2020 Aug 1;10(8):2523-2534. eCollection 2020. Am J Cancer Res. 2020. PMID: 32905529 Free PMC article.
• Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer.

  Jiang G, Teramoto Y, Goto T, Mizushima T, Inoue S, Ide H, Nagata Y, Kashiwagi E, Baras AS, Netto GJ, Yang Z, Miyamoto H. Jiang G, et al. Cancers (Basel). 2021 Feb 26;13(5):975. doi: 10.3390/cancers13050975. Cancers (Basel). 2021. PMID: 33652650 Free PMC article.